Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESCIO neoadjuvant immuno-oncology in clear cell RCC
2024-515514-40-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in clear cell renal cell carcinoma (ccRCC) comparing Relatlimab + nivolumab neoadjuvant with Relatlimab + nivolumab + ipilimumab neoadjuvant (2 arms). Primary endpoint: Pathologic response rate. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-515514-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515514-40-00.